Transform Wealth LLC Has $610,000 Position in Johnson & Johnson (NYSE:JNJ)

Transform Wealth LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 13.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,679 shares of the company’s stock after selling 590 shares during the quarter. Transform Wealth LLC’s holdings in Johnson & Johnson were worth $610,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of JNJ. Tallon Kerry Patrick bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $290,000. Capital & Planning LLC raised its position in shares of Johnson & Johnson by 13.6% in the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company’s stock worth $221,000 after acquiring an additional 183 shares in the last quarter. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA bought a new position in shares of Johnson & Johnson in the 4th quarter worth about $85,886,000. Finally, Apollon Wealth Management LLC grew its stake in shares of Johnson & Johnson by 20.7% in the 4th quarter. Apollon Wealth Management LLC now owns 105,500 shares of the company’s stock valued at $15,257,000 after buying an additional 18,082 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $155.19 on Thursday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market cap of $373.41 billion, a P/E ratio of 23.34, a PEG ratio of 2.56 and a beta of 0.42. The firm has a 50-day moving average of $153.56 and a 200 day moving average of $153.70. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.35%. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

JNJ has been the subject of several research reports. Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Raymond James lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a report on Monday, April 14th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 16th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 5th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.